Dosing & Administration
Dosing may be titrated according to the following schedule, but titration can be adjusted based on efficacy and tolerability:
1-Week
titration1
titration1
Day 1
12.5 mg
Days 2-3
25 mg/day
(12.5 mg twice daily)
Days 4-7
50 mg/day
(25 mg twice daily)
Recommended
dose
dose
100 mg/day (50 mg twice daily)
The dose may be increased to 200 mg/day
(100 mg twice daily), based on individual patient response.
Doses above 200 mg/day have not been studied1
- Twice-daily (AM/PM) dosing with or without a meal1
- Taking Savella with a meal may improve tolerability
- Savella should be tapered and not abruptly discontinued after extended use1
Savella is non-narcotic and is not scheduled.1
No dosage adjustment needed for patients with hepatic impairment or mild renal impairment1
- As with any drug, caution should be exercised in patients with severe hepatic impairment
- Savella should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease
- Savella should be used with caution in patients with moderate renal impairment
- In patients with severe renal impairment, the maintenance dose should be reduced by 50%
- Savella is not recommended for patients with end-stage renal disease
Savella (milnacipran HCl) is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients.
Please also see Full Prescribing Information.
